Benjamine Liu, TrialSpark CEO

Paul Hud­son and Tri­alSpark's mu­tu­al de­sire to speed up de­vel­op­ment con­verges in three-year, six-drug goal

A uni­corn start­up that orig­i­nal­ly set out to has­ten clin­i­cal stud­ies for bio­phar­ma part­ners dug fur­ther in­to its re­vised path of in­ter­nal drug de­vel­op­ment by link­ing arms with Sanofi in a pact that the biotech’s CEO said orig­i­nat­ed from the top.

Tri­alSpark and the Big Phar­ma on Tues­day com­mit­ted to in-li­cens­ing and/or ac­quir­ing six Phase II/Phase III drugs with­in the next three years.

“I’ve known Paul Hud­son for a while and we were dis­cussing the op­por­tu­ni­ty to re­al­ly re-imag­ine a lot of dif­fer­ent parts of phar­ma,” Tri­alSpark CEO Ben­jamine Liu told End­points News, “and one of the things that we dis­cussed was this op­por­tu­ni­ty to ac­cel­er­ate the de­vel­op­ment of new med­i­cines in mu­tu­al ar­eas of in­ter­est.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.